Agilent announces immunoassay kit to detect sars-cov-2 antibodies

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced the launch of the agilent dako sars-cov-2 igg enzyme-linked immunosorbent assay (elisa) kit intended for the qualitative detection of immunoglobulin g (igg) antibodies to sars-cov-2 in human serum or plasma. the kit, which marks agilent's entrance into sars-cov-2 testing in the us, has completed the notification process to fda in accordance with section iv.d of fda's “policy for coronavirus disease-2019 te
A Ratings Summary
A Quant Ranking